This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, F. Search for Related Content PubMed PubMed Citation Articles by Chen, F. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers

Endogenous Inhibitors of Nuclear Factor-B, An Opportunity for Cancer Control

The Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia

Excessive and prolonged activation of nuclear factor-B (NF-B) has been linked to numerous human diseases, especially cancer, because of the elevated expression of genes encoding antiapoptotic proteins, cytokines, chemokines, cell adhesion molecules, and so on. Eukaryotic cells have developed multiple mechanisms to keep this ubiquitous transcription factor in check. In addition to the inhibitor of B family proteins, a number of endogenous molecules that negatively regulate the activation or activity of NF-B have been identified. These molecules include A20, CYLD, cyPG15-deoxy-^12,14-prostaglandin J₂, Foxj1, Twist proteins, and ß-arrestins. The extended list of these endogenous inhibitors of NF-B may provide new opportunities for the development of novel strategies for the intervention of malignant transformation. The question to be asked is how NF-B is sustained activated in a number of cancers in which so many antagonists are surrounded.

This article has been cited by other articles:

				C. Sourbier, S. Danilin, V. Lindner, J. Steger, S. Rothhut, N. Meyer, D. Jacqmin, J.-J. Helwig, H. Lang, and T. Massfelder Targeting the Nuclear Factor-{kappa}B Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy Cancer Res., December 15, 2007; 67(24): 11668 - 11676. [Abstract] [Full Text] [PDF]

				W. J. E. Tissing, M. L. den Boer, J. P. P. Meijerink, R. X. Menezes, S. Swagemakers, P. J. van der Spek, S. E. Sallan, S. A. Armstrong, and R. Pieters Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells Blood, May 1, 2007; 109(9): 3929 - 3935. [Abstract] [Full Text] [PDF]

				Y Zhou, S Eppenberger-Castori, U Eppenberger, and C C Benz The NF{kappa}B pathway and endocrine-resistant breast cancer Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S37 - S46. [Abstract] [Full Text] [PDF]